Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses

Frye, Mark A.; McElroy, Susan L.; Fuentes, Manuel; Sutor, Bruce; Schak, Kathryn M.; Galardy, Christine; Palmer, Brian A.; Prieto, Miguel L.; Kung, Simon; Sola, Christopher L.; Ryu, Euijung; Veldić, Marin; Geske, Jennifer R.; Cuellar-Barboza, Alfredo B.; Seymour, Lisa R.; Mori, Nicole; Crowe, Scott; Rummans, Teresa A.; Biernacka, Joanna M.

doi:10.1186/s40345-015-0030-4

Cited by 60 publications

(65 citation statements)

References 30 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study contained three participant groups: pediatric and adolescent BD patients from the TEAM study (n = 82), adult BD patients from the Mayo Clinic Bipolar Disorder Biobank (n = 855) , and an adult healthy control group from the Mayo Clinic Biobank (n = 857) . The TEAM study was a randomized clinical trial comparing antimanic treatments .…”

Section: Methodsmentioning

confidence: 99%

Association of brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism with early‐onset bipolar disorder

et al. 2015

Self Cite

View full text Add to dashboard Cite

Objectives Brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) functional polymorphism has been implicated in early-onset bipolar disorder. However, results of studies are inconsistent. We aimed to further explore this association. Methods DNA samples from the Treatment of Early Age Mania (TEAM) and Mayo Clinic Bipolar Disorder Biobank were investigated for association of rs6265 with early-onset bipolar disorder. Bipolar cases were classified as early onset with the definition of first manic or depressive episode at age ≤ 19 years (versus adult-onset cases at age > 19 years). After quality control, 69 TEAM early-onset bipolar disorder cases, 725 Mayo Clinic bipolar disorder cases (including 189 early onset cases), and 764 controls were included in the analysis of association, assessed with logistic regression assuming log-additive allele effects. Results Comparison of TEAM cases with controls suggested association of early-onset bipolar disorder with the rs6265 minor allele [odds ratio (OR) = 1.55, p = 0.04]. Although comparison of early-onset adult bipolar disorder cases from Mayo Clinic versus controls was not statistically significant, the OR estimate indicated the same direction of effect (OR = 1.21, p = 0.19). When the early-onset TEAM and Mayo Clinic early-onset adult groups were combined and compared with the control group, the association of the minor allele rs6265 was statistically significant (OR = 1.30, p = 0.04). Conclusions These preliminary analyses of a relatively small sample with early-onset bipolar disorder are suggestive that functional variation in BDNF is implicated in bipolar disorder risk and may have a more significant role in early-onset expression of the disorder.

show abstract

Section: Methodsmentioning

confidence: 99%

Association of brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism with early‐onset bipolar disorder

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…The low participation rate of African‐Americans in bipolar disorder genetic research speaks to the need to increase engagement of these populations in research; however, recruitment of African‐Americans for genetic research (and bipolar disorder studies more specifically) is challenging (Table ). For example, the Mayo Clinic Bipolar Biobank has about 2148 individuals enrolled, but only 3.7% are of African ancestry . Even with policy initiatives from the National Institute of Mental Health (NIMH) aimed at increasing minority participation, results have been mixed.…”

Section: Genomic Studies Of Bipolar Disorder: Underrepresentation Of mentioning

confidence: 99%

Racial disparities in bipolar disorder treatment and research: a call to action

et al. 2018

Self Cite

View full text Add to dashboard Cite

ObjectivesHealth disparities between individuals of African and European ancestry are well documented. The disparities in bipolar disorder may be driven by racial bias superimposed on established factors contributing to misdiagnosis, including: evolving empirically based diagnostic criteria (International Classification of Diseases [ICD], Research Diagnostic Criteria [RDC] and Diagnostic and Statistical Manual [DSM]), multiple symptom domains (i.e. mania, depression and psychosis), and multimodal medical and additional psychiatric comorbidity.MethodsFor this paper, we reviewed the phenomenological differences between bipolar individuals of African and European ancestry in the context of diagnostic criteria and clinical factors that may contribute to a potential racial bias.ResultsPublished data show that bipolar persons of African ancestry, compared with bipolar persons of non‐African ancestry, are more often misdiagnosed with a disease other than bipolar disorder (i.e. schizophrenia). Additionally, studies show that there are disparities in recruiting patients of African ancestry to participate in important genomic studies. This gap in biological research in this underrepresented minority may represent a missed opportunity to address potential racial differences in the risk and course of bipolar illness.ConclusionA concerted effort by the research community to increase inclusion of diverse persons in studies of bipolar disorder through community engagement may facilitate fully addressing these diagnostic and treatment disparities in bipolar individuals of African ancestry.

show abstract

“…Administrative oversight has been provided by the co‐principal investigators (MAF and JMB) and their Executive Committee, the Mayo Clinic Biospecimen Trust Oversight Group, and the Center for Individualized Medicine . The design, infrastructure, aims, and research uses of the biobank, along with demographics and clinical features of the first enrolled participants, are described elsewhere .…”

mentioning

confidence: 99%

National Survey and Community Advisory Board Development for a Bipolar Disorder Biobank

Frye

Doederlein²,

Koenig

et al. 2015

Bipolar Disorders

Self Cite

View full text Add to dashboard Cite

Objectives To engage a national advocacy group and local stakeholders for guidance in developing a bipolar disorder biobank through a web-based survey and a community advisory board. Methods The Depression and Bipolar Support Alliance and the Mayo Clinic Bipolar Biobank conducted a national web-based survey inquiring about interest in participating in a biobank (i.e., giving DNA and clinical information). A community advisory board was convened to guide establishment of the biobank and identify key deliverables from the research project and for the community. Results Among 385 survey respondents, funding source (87%), professional opinion (76%), mental health consumer opinion (79%), and return of research results (91%) were believed to be important for considering study participation. Significantly more patients were willing to participate in a biobank managed by a university or clinic (78.2%) than one managed by government (63.4%) or industry (58.2%; both p < 0.001). The nine-member community advisory board expressed interest in research to help predict the likelihood of bipolar disorder developing in a child of an affected parent and which medications to avoid. The advisory board endorsed the use of a comprehension questionnaire to evaluate participants' understanding of the study (e.g., longevity of DNA specimens, right to remove samples, accessing medical records) as a means to strengthen the informed-consent process. Conclusions These national survey and community advisory data support the merit of establishing a biobank to enable studies of disease risk, provided that health records and research results are adequately protected. The goals of earlier diagnosis and individualized treatment of bipolar disorder were endorsed.

show abstract

Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses

Cited by 60 publications

References 30 publications

Association of brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism with early‐onset bipolar disorder

Association of brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism with early‐onset bipolar disorder

Racial disparities in bipolar disorder treatment and research: a call to action

National Survey and Community Advisory Board Development for a Bipolar Disorder Biobank

Contact Info

Product

Resources

About